{"organizations": [], "uuid": "29a3e87665b367cd1aa3b2ef99d81b48a1af121c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180427.html", "section_title": "Archive News &amp; Video for Friday, 27 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/swiss-ipo-polyphor/polyphor-ipo-price-range-set-at-30-40-swiss-francs-idUSZ8N1QN02P", "country": "US", "domain_rank": 408, "title": "Polyphor IPO price range set at 30-40 Swiss francs", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.376, "site_type": "news", "published": "2018-04-27T13:23:00.000+03:00", "replies_count": 0, "uuid": "29a3e87665b367cd1aa3b2ef99d81b48a1af121c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/swiss-ipo-polyphor/polyphor-ipo-price-range-set-at-30-40-swiss-francs-idUSZ8N1QN02P", "ord_in_thread": 0, "title": "Polyphor IPO price range set at 30-40 Swiss francs", "locations": [], "entities": {"persons": [{"name": "murepavadin", "sentiment": "none"}, {"name": "john revill", "sentiment": "none"}, {"name": "biju dwarakanath", "sentiment": "none"}, {"name": "polyphor", "sentiment": "none"}], "locations": [{"name": "zurich", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "polyphor ipo-poly", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH, April 27 (Reuters) - Specialty pharmaceuticals company Polyphor IPO-POLY.S on Friday announced a price range of 30-40 Swiss francs ($30.33-$40.44)per share for its upcoming flotation - the latest company to seek a listing on the Swiss stock exchange.\nThe Swiss company said it is aiming to raise 100-150 million francs in an all-primary offering, with trading expected to start on or around May 15.\nPolyphor said it would use the funds to develop Murepavadin, a drug to treat a strain of pneumonia with high levels of mortality. ($1 = 0.9890 Swiss francs) (Reporting by John Revill; Editing by Biju Dwarakanath)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-27T13:23:00.000+03:00", "crawled": "2018-04-28T12:26:45.011+03:00", "highlightTitle": ""}